Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP13512 Maintenance in RLS
NCT00311363Phase 3Completed
- Sponsor
- XenoPort, Inc.
- Start
- Apr 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in restless legs syndrome (RLS) comparing GEn (XP13512) 1200 mg with Placebo (2 arms). Primary endpoint: Percentage of Participants Who Experienced a Relapse During the Double-Blind Treatment Period at 36 weeks. Started Apr 2006; status: completed.
02
Drugs
gabapentin enacarbil
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT00311363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00311363.